PubRank

C A Ludlam

Author PubWeight™ 157.23‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers. J Virol 1990 6.73
2 Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1. J Virol 1990 5.20
3 Guidelines for the management of hemophilia. Haemophilia 2012 5.16
4 Detection of a novel DNA virus (TTV) in blood donors and blood products. Lancet 1998 5.15
5 Convergent and divergent sequence evolution in the surface envelope glycoprotein of human immunodeficiency virus type 1 within a single infected patient. Proc Natl Acad Sci U S A 1992 3.58
6 Discontinuous sequence change of human immunodeficiency virus (HIV) type 1 env sequences in plasma viral and lymphocyte-associated proviral populations in vivo: implications for models of HIV pathogenesis. J Virol 1991 3.34
7 Infection with hepatitis G virus among recipients of plasma products. Lancet 1996 3.25
8 Concurrent evolution of human immunodeficiency virus type 1 in patients infected from the same source: rate of sequence change and low frequency of inactivating mutations. J Virol 1990 2.68
9 Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost 1998 2.20
10 Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet 1997 2.19
11 The end of the heparin pump? Low molecular weight heparin has many advantages over unfractionated heparin. BMJ 1998 2.13
12 Human T-lymphotropic virus type III (HTLV-III) infection in seronegative haemophiliacs after transfusion of factor VIII. Lancet 1985 2.08
13 Hepatitis C quantification and sequencing in blood products, haemophiliacs, and drug users. Lancet 1990 2.01
14 New-variant Creutzfeldt-Jakob disease and treatment of haemophilia. Executive Committee of the UKHCDO. United Kingdom Haemophilia Centre Directors' Organisation. Lancet 1997 1.94
15 Detection, quantification and sequencing of HIV-1 from the plasma of seropositive individuals and from factor VIII concentrates. AIDS 1991 1.93
16 Early increase in levels of soluble inter-cellular adhesion molecule-1 (sICAM-1); potential risk factor for the acute coronary syndromes. Eur Heart J 2001 1.87
17 Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. Circulation 1999 1.79
18 Interleukin 6 and haemostasis. Br J Haematol 2001 1.75
19 Acquired haemophilia and its management. Br J Haematol 1995 1.69
20 Treatment for haemophilia by postcode. BMJ 1997 1.67
21 Determinants of HIV disease progression: six-year longitudinal study in the Edinburgh haemophilia/HIV cohort. Lancet 1991 1.58
22 Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood 1993 1.46
23 The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study. Thromb Haemost 1997 1.45
24 Coagulation and fibrinolysis in patients undergoing operation for ruptured and nonruptured infrarenal abdominal aortic aneurysms. J Vasc Surg 1999 1.44
25 Fibrinolytic actions of intra-arterial angiotensin II and bradykinin in vivo in man. Cardiovasc Res 2000 1.43
26 HLA haplotype A1 B8 DR3 as a risk factor for HIV-related disease. Lancet 1988 1.41
27 Venous occlusion does not release von Willebrand factor, factor VIII or PAI-1 from endothelial cells--the importance of consensus on the use of correction factors for haemoconcentration. Thromb Haemost 1993 1.40
28 Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Circulation 1999 1.40
29 Management of acquired von Willebrand's syndrome in a patient requiring major surgery. Haemophilia 2005 1.40
30 Confirmation of non-infection in persistently HIV-seronegative recipients of contaminated factor VIII. Lancet 1990 1.39
31 The effects of low-dose testosterone treatment on lipid metabolism, clotting factors and ultrasonographic ovarian morphology in women. Clin Endocrinol (Oxf) 1998 1.38
32 Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis. Circulation 2001 1.32
33 The release of a human platelet specific protein measured by a radioimmunoassay. Thromb Res 1975 1.31
34 TT virus--part of the normal human flora? J Infect Dis 1999 1.29
35 HIV antigen and antibody detection: variable responses to infection in the Edinburgh haemophiliac cohort. Br Med J (Clin Res Ed) 1988 1.27
36 Frequent reinfection and reactivation of hepatitis C virus genotypes in multitransfused hemophiliacs. J Infect Dis 1994 1.23
37 Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: plasma factor VII activity of 10 IU/ml is associated with an increased incidence of bleeding. Thromb Haemost 2001 1.12
38 Studies on liberation of beta-thromboglobulin from human platelets in vitro. Br J Haematol 1976 1.10
39 Discrimination of hepatitis G virus/GBV-C geographical variants by analysis of the 5' non-coding region. J Gen Virol 1997 1.09
40 Evolution of zidovudine resistance-associated genotypes in human immunodeficiency virus type 1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1996 1.07
41 Audit of oral anticoagulant treatment. The BCSH Haemostasis and Thrombosis Task Force of the British Society for Haematology. J Clin Pathol 1993 1.06
42 Use of several second generation serological assays to determine the true prevalence of hepatitis C virus infection in haemophiliacs treated with non-virus inactivated factor VIII and IX concentrates. Br J Haematol 1992 1.02
43 Myocardial dysfunction in patients infected with HIV: prevalence and risk factors. Br Heart J 1992 1.02
44 EUHASS: The European Haemophilia Safety Surveillance system. Thromb Res 2011 1.02
45 Phosphodiesterase type 5 inhibition does not reverse endothelial dysfunction in patients with coronary heart disease. Heart 2005 1.01
46 A comparative study using immunological and biological assay of the haemostatic responses to DDAVP infusion venous occlusion and exercise in normal men. Thromb Haemost 1984 1.01
47 An in vivo model for the assessment of acute fibrinolytic capacity of the endothelium. Thromb Haemost 1997 1.00
48 Three approaches to the radioimmunoassay of human beta-thromboglobulin. Br J Haematol 1976 0.99
49 Five year prospective study of HIV infection in the Edinburgh haemophiliac cohort. BMJ 1990 0.99
50 HTLV-III infection associated with glandular-fever-like illness in a haemophiliac. Lancet 1985 0.98
51 The procoagulant potential of environmental particles (PM10). Occup Environ Med 2005 0.98
52 New rapid method for diagnosis of deep venous thrombosis. Lancet 1975 0.97
53 Antenatal diagnosis. Baillieres Clin Haematol 1991 0.96
54 A radioimmunoassay for platelet factor 4. Thromb Res 1976 0.95
55 Emotional impact of diagnosis and early treatment of lymphomas. J Psychosom Res 1984 0.92
56 Less severe bleeding in hemophilia B than in hemophilia A. J Thromb Haemost 2008 0.92
57 Effects of acute liver injury on blood coagulation. J Thromb Haemost 2003 0.92
58 An HIV positive haemophiliac with acute lymphoblastic leukaemia successfully treated with intensive chemotherapy and syngeneic bone marrow transplantation. Bone Marrow Transplant 1992 0.92
59 The treatment of acquired factor VIII inhibitors: worldwide experience with porcine factor VIII concentrate. International Acquired Hemophilia Study Group. Semin Hematol 1993 0.91
60 Heterogeneity of hepatitis C virus genotypes in hemophilia: relationship with chronic liver disease. Blood 1995 0.90
61 Coagulopathy and hyperfibrinolysis in ruptured abdominal aortic aneurysm repair. Ann Vasc Surg 2004 0.89
62 Prothrombin time to assess fulminant hepatic failure. Lancet 2002 0.89
63 Abnormalities of circulating lymphocyte subsets in haemophiliacs in an AIDS-free population. Lancet 1984 0.89
64 Investigation of the relative infectivity and pathogenicity of different hepatitis C virus genotypes in hemophiliacs. Blood 1996 0.89
65 Prevalence of pernicious anaemia in patients with Type 1 diabetes mellitus and autoimmune thyroid disease. Diabet Med 2000 0.89
66 Evidence for the platelet specificity of beta-thromboglobulin and studies on its plasma concentration in healthy individuals. Br J Haematol 1979 0.88
67 Interferon treatment for chronic hepatitis C infection in hemophiliacs--influence of virus load, genotype, and liver pathology on response. Blood 1996 0.88
68 Low proteins C and S and activation of fibrinolysis in treated essential thrombocythemia. Am J Hematol 1995 0.88
69 Biovigilance and pharmacovigilance for haemophilia. Haemophilia 2010 0.87
70 Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol 1994 0.87
71 Thrombosis in a duplicated superficial femoral vein in a patient with haemophilia A. Haemophilia 2000 0.86
72 European curriculum for thrombosis and haemostasis. Haemophilia 2009 0.86
73 The coagulative and cardiorespiratory responses to reamed intramedullary nailing of isolated fractures. J Bone Joint Surg Br 2001 0.86
74 Human parvovirus B19 and blood products. Vox Sang 1997 0.85
75 Haematological indices in elderly patients with epistaxis. Health Bull (Edinb) 1988 0.84
76 Transcriptional activation of the factor VIII gene in liver cell lines by interleukin-6. Thromb Haemost 1998 0.84
77 Plasminogen assay by a haemagglutination inhibition technique. J Clin Pathol 1971 0.84
78 An immunoradiometric assay for procoagulant factor VIII antigen: results in haemophilia, von Willebrand's disease and fetal plasma and serum. Br J Haematol 1979 0.83
79 Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitors. Haemophilia 2009 0.83
80 Factor VII and fibrinolytic response to deamino-8-D-argenine vasopressin in normal subjects and dissociate response in some patients with haemophilia and von Willebrand's disease. Br J Haematol 1980 0.83
81 Investigation of chronic hepatitis C infection in individuals with haemophilia: assessment of invasive and non-invasive methods. Br J Haematol 1996 0.82
82 Does avascular necrosis cause collapse of the dome of the talus in severe haemophilia? Haemophilia 1999 0.82
83 Effect of glycaemic control, metformin and gliclazide on platelet density and aggregability in recently diagnosed type 2 (non-insulin-dependent) diabetic patients. Diabete Metab 1990 0.82
84 Carrier detection in haemophilia a by immunological measurement of factor VIII related antigen (VIIIRAg) and factor VIII clotting antigen (VIIICAg). Br J Haematol 1981 0.82
85 The L-arginine/nitric oxide pathway contributes to the acute release of tissue plasminogen activator in vivo in man. Cardiovasc Res 1998 0.81
86 Platelet-density analysis and intraplatelet granule content in young insulin-dependent diabetics. Diabetes 1986 0.81
87 Immunological studies in HIV seronegative haemophiliacs: relationships to blood product therapy. Br J Haematol 1992 0.81
88 Coagulation and fibrinolytic systems in type I diabetes: effects of venous occlusion and insulin-induced hypoglycaemia. Clin Sci (Lond) 1993 0.81
89 Polycythaemia and HIV infection. Lancet 1990 0.81
90 Disordered immune regulation in haemophiliacs not exposed to commercial factor VIII. Lancet 1983 0.81
91 Patterns of hepatitis G viraemia and liver disease in haemophiliacs previously exposed to non-virus inactivated coagulation factor concentrates. Thromb Haemost 1998 0.81
92 Osteolytic bone lesions in a patient with idiopathic myelofibrosis and bronchial carcinoma. J Clin Pathol 1995 0.80
93 Measurement of platelet volume using a variety of different anticoagulant and antiplatelet mixtures. Blood Coagul Fibrinolysis 1996 0.80
94 ACP Broadsheet 122: August 1989. Platelet function testing. J Clin Pathol 1989 0.80
95 Acquired haemophilia in recipients of depot thioxanthenes. Haemophilia 2000 0.80
96 Aortic aneurysms and consumptive coagulopathy. Blood Coagul Fibrinolysis 1991 0.80
97 The use of porcine factor VIII in the treatment of patients with acquired hemophilia: the United Kingdom experience. Am J Med 1991 0.80
98 Thrombosis and disseminated intravascular coagulation following treatment with the prothrombin complex concentrate, DEFIX. Thromb Haemost 1999 0.80
99 An unusual case of amyloidosis complicating light chain myeloma. Acta Haematol 1991 0.79
100 Human immunodeficiency virus detection: correlation with clinical progression in the Edinburgh haemophiliac cohort. Br J Haematol 1989 0.79
101 Haemostatic effects of supraphysiological levels of testosterone in normal men. Thromb Haemost 1995 0.79
102 Immunological abnormalities in haemophiliacs. Blood Rev 1992 0.79
103 Hemophilic arthropathy of the upper limb. Clin Orthop Relat Res 1987 0.79
104 Individualized heparin and protamine management in infants and children undergoing cardiac operations. Ann Thorac Surg 2001 0.79
105 Stevens-Johnson syndrome associated with methotrexate treatment for non-Hodgkin's lymphoma. Ulster Med J 1993 0.79
106 Proposal to establish a European Association for Hemophilia and Allied Disorders. J Thromb Haemost 2006 0.78
107 Acute endothelial tissue plasminogen activator release in pregnancy. J Thromb Haemost 2008 0.78
108 Development of anti-interferon antibodies and breakthrough hepatitis during treatment for HCV infection in haemophiliacs. Br J Haematol 1996 0.78
109 Hypercholesterolaemia and lipid lowering treatment do not affect the acute endogenous fibrinolytic capacity in vivo. Heart 2002 0.78
110 Hepatitis C infection and outcomes in the Scottish haemophilia population. Haemophilia 2013 0.77
111 Common peroneal nerve entrapment in a hemophiliac. Clin Orthop Relat Res 1983 0.77
112 A comparison between the plasma concentration of immunologically assayed platelet factor 4 and beta-thromboglobulin and the heparin thrombin clotting time. Thromb Res 1979 0.77
113 von Willebrand factor and platelet count in ruptured abdominal aortic aneurysm repair. Eur J Vasc Endovasc Surg 2003 0.77
114 Tissue-type plasminogen activator and plasminogen activator inhibitor activities as predictors of adverse events in unstable angina. Am J Cardiol 1994 0.77
115 New-variant Creutzfeldt-Jakob disease and treatment of haemophilia. Executive Committee UK Haemophilia Directors' Organisation. Lancet 1998 0.76
116 Raised plasma endothelin in unstable angina and non-Q wave myocardial infarction: relation to cardiovascular outcome. Br Heart J 1994 0.76
117 Dilated cardiomyopathy in haemophiliacs infected with the human immunodeficiency virus. Scott Med J 1993 0.76
118 Guidelines on the diagnosis, management and prevention of hepatitis in haemophilia. Haemophilia 2001 0.76
119 Recommendations for the treatment of factor VIII inhibitors: from the UK Haemophilia Centre Directors' Organisation Inhibitor Working Party. Blood Coagul Fibrinolysis 1996 0.76
120 The management of 'low-risk' and 'intermediate-risk' patients with primary thrombocythaemia. MPD (UK) Study Group. Br J Haematol 1999 0.75
121 Incidence of infection with hepatitis B virus in 56 patients with haemophilia A 1971-1979. J Clin Pathol 1983 0.75
122 AIDS: the alternative view. Lancet 1992 0.75
123 Plasma microparticles are not elevated in fresh plasma from patients with gynaecological malignancy--an observational study. Gynecol Oncol 2011 0.75
124 Platelet and fibrinogen survival in acute promyelocytic leukaemia. Br Med J 1976 0.75
125 High purity factor IX and prothrombin complex concentrate (PCC): pharmacokinetics and evidence that factor IXa is the thrombogenic trigger in PCC. Thromb Haemost 1996 0.75
126 Liver biopsy in haemophilia. Br J Haematol 1997 0.75
127 HIV progression and immune activation. Lancet 1993 0.75
128 Human parvovirus B19 infection in persons with haemophilia. Thromb Haemost 1998 0.75
129 No effect of aspirin on beta-thromboglobulin plasma levels in healthy volunteers. Thromb Res 1981 0.75
130 Safety, efficacy and cost-effectiveness of home therapy with recombinant activated factor VII in a patient with severe haemophilia A and an anti-factor VIII inhibitor. Blood Coagul Fibrinolysis 1998 0.75
131 Tissue plasminogen activator genetic polymorphisms do not influence tissue plasminogen activator release in patients with coronary heart disease. J Thromb Haemost 2006 0.75
132 Hepatitis B infection in hemophilia. Lancet 1982 0.75
133 The successful use of plasma exchange and immunosuppression in the management of acquired Glanzmann's thrombasthenia. Br J Haematol 2002 0.75
134 The fibrinolytic system and proteins C and S in treated polycythaemia rubra vera. Blood Coagul Fibrinolysis 1992 0.75
135 Linking the world with training and research for improving haemophilia care. Haemophilia 2008 0.75
136 Warfarin-induced skin necrosis. Postgrad Med J 1999 0.75
137 Lesser sac haematoma in a haemophiliac patient. Br J Radiol 1985 0.75
138 Is albumin harmful? Br J Haematol 1999 0.75
139 Survival of 111-indium platelet subpopulations of varying density in normal and post splenectomized subjects. Br J Haematol 1986 0.75
140 Therapeutic concentrates for the treatment of congenital deficiencies of factors VII, XI, and XIII. Semin Thromb Hemost 1993 0.75
141 Reliability of a single beta-thromboglobulin measurement in a diabetic population: importance of PGE1 in anticoagulant mixture. Damad Study Group. Thromb Haemost 1987 0.75
142 DDAVP shortens the bleeding time in Bernard-Soulier syndrome. Thromb Res 1988 0.75
143 Immunohistological diagnosis of a case of composite lymphoma. Br J Haematol 1987 0.75
144 Acquired factor VIII inhibitor associated with multiple sclerosis, successfully treated with porcine factor VIII. Thromb Haemost 1987 0.75
145 Recombinant coagulation factors. Blood Rev 1997 0.75
146 The assessment of platelet function in vivo by measurement of beta-thromboglobulin, platelet factor 4 and platelet survival. Artery 1980 0.75
147 Enhancement of human T cell responses to allogeneic stimuli by factor VIII concentrates. Br J Haematol 1992 0.75
148 Platelet and coagulation function in patients with abnormal cardiac valves treated with sulphinpyrazone. Thromb Haemost 1981 0.75
149 Inhibition of thrombin activatable fibrinolysis inhibitor augments fibrinolysis in human whole blood. J Thromb Haemost 2005 0.75
150 beta-Thromboglobulin test. Lancet 1977 0.75
151 Unexplained haemolytic anaemia in successive pregnancies with negative direct antiglobulin test and response to high dose i.v. IgG. Br J Obstet Gynaecol 1994 0.75
152 Proceedings: A radioimmunoassay for human platelet beta-thromboglobulin. Thromb Diath Haemorrh 1975 0.75
153 Efficacy of heat treatment of factor VIII concentrate. Vox Sang 1988 0.75
154 Absence of hepatitis A virus transmission by high-purity solvent detergent treated coagulation factor concentrates in Scottish haemophiliacs. Br J Haematol 1995 0.75
155 Transfusion associated graft-versus-host disease in T-cell chronic lymphocytosis. Br J Haematol 1988 0.75
156 TGF-beta is not the principal immunosuppressive component in coagulation factor concentrates. Br J Haematol 1999 0.75
157 Oesophageal candidiasis in an HIV-negative individual treated with factor VIII concentrate. Thromb Haemost 1992 0.75
158 Haemophilia B and factor IX mutations. Lancet 1993 0.75
159 Study of endothelial t-PA and vWf in normal subjects and in von Willebrand's disease. Blood Coagul Fibrinolysis 1994 0.75
160 Immune status in HIV-1-infected men and boys with haemophilia in the United Kingdom. UK Haemophilia Centre Directors' Organisation. AIDS 1998 0.75
161 Local and systemic effects of intra-arterial desmopressin in healthy volunteers and patients with type 3 von Willebrand disease. Role of interleukin-6. Thromb Haemost 2000 0.75
162 The effect of monoclonal or ion-exchange purified factor VIII concentrate on HIV disease progression: a prospective cohort comparison. Br J Haematol 1998 0.75
163 Variant Creutzfeldt-Jakob disease. Transfus Med Rev 2000 0.75